Search Results

Illumina, Inc. announced the successful completion of the spin-off of GRAIL. This milestone follows the company’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company.

GRAIL, Inc. announced its spin-off from Illumina is complete, and GRAIL will be listed and commence regular-way trading on the Nasdaq under the symbol “GRAL” as of tomorrow, June 25, 2024.

Illumina, Inc. announced that its Board of Directors has approved the spin-off of GRAIL.

GRAIL Leadership to Outline Early Cancer Detection Market Opportunity, Business Strategy, and Financial Profile MENLO PARK, Calif.--( BUSINESS WIRE )-- GRAIL, LLC., a healthcare company whose mission is to detect cancer early when it can be cured, today will host a virtual Capital Markets Day. Members from GRAIL’s management team will outline growth drivers for Galleri ® , a clinically validated, commercially available multi-cancer early detection test, as well as the Company’s scien

After being spun off of sequencing giant Illumina, Grail on Tuesday is set to start trading on the Nasdaq Global Select Market following a years-long antitrust battle with regulators.

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced it has received approval of its divestment plan for GRAIL from the European Commission.